tiprankstipranks
Treatment.com International (TREIF)
OTHER OTC:TREIF

Treatment.com International (TREIF) Stock Price & Analysis

10 Followers

TREIF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.02 - $1.20
Previous Close$0.52
Volume14.01K
Average Volume (3M)7.80K
Market Cap
$3.40M
Enterprise Value$3.90M
Total Cash (Recent Filing)C$474.00
Total Debt (Recent Filing)C$686.01K
Price to Earnings (P/E)-2.0
Beta0.58
Apr 29, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding37,105,115
10 Day Avg. Volume15,269
30 Day Avg. Volume7,801
Standard Deviation0.31
R-Squared0.00655
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)-9.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-131.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

TREIF FAQ

What was Treatment.com International’s price range in the past 12 months?
Treatment.com International lowest stock price was $0.02 and its highest was $1.20 in the past 12 months.
    What is Treatment.com International’s market cap?
    Currently, no data Available
    When is Treatment.com International’s upcoming earnings report date?
    Treatment.com International’s upcoming earnings report date is Apr 29, 2024 which is 5 days ago.
      How were Treatment.com International’s earnings last quarter?
      Treatment.com International released its earnings results on Nov 28, 2023. The company reported -$0.088 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.088.
        Is Treatment.com International overvalued?
        According to Wall Street analysts Treatment.com International’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Treatment.com International pay dividends?
          Treatment.com International does not currently pay dividends.
          What is Treatment.com International’s EPS estimate?
          Treatment.com International’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Treatment.com International have?
          Treatment.com International has 6,619,499 shares outstanding.
            What happened to Treatment.com International’s price movement after its last earnings report?
            Treatment.com International reported an EPS of -$0.088 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.143%.
              Which hedge fund is a major shareholder of Treatment.com International?
              Currently, no hedge funds are holding shares in TREIF
              ---

              Company Description

              Treatment.com International

              Treatment.com International Inc operates in the mobile health, digital health, telemedicine, and artificial intelligence segments of the global health industry. Its first commercial mobile application is an internally-developed medical intelligence platform, code-named as MERLIN. Multiple pre-production versions of MERLIN are running in multiple Google Cloud Datacenters in the U.S., Canada, and Singapore. The scale and scope of Google Cloud Services provide the company with the data centers and software services needed to provide its diagnostic and treatment services to a global customer base, in multiple languages.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Teladoc
              T2 Biosystems
              Zoetis
              Idexx Laboratories
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis